Skip to main navigation Skip to search Skip to main content

A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma

  • Catherine S. Diefenbach
  • , Opeyemi Jegede
  • , Victoria Wang
  • , Stephen M. Ansell
  • , Lale Kostakoglu
  • , Christian Steidl
  • , Yasodha Natkunam
  • , David W. Scott
  • , Richard F. Ambinder
  • , Kevin A. David
  • , Ranjana H. Advani
  • , Nancy L. Bartlett
  • , Michael A. Roberston
  • , Sachdev P. Thomas
  • , Jonathon Cohen
  • , Sami Ibrahimi
  • , Gaurav Goyal
  • , Neha Mehta-Shah
  • , Jennifer E. Amengual
  • , Christopher J. Forlenza
  • Peter D. Cole, Fenghai Duan, Kara Kelly, Brad S. Kahl
  • New York University
  • Dana-Farber Cancer Institute
  • Mayo Clinic Rochester, MN
  • University of Virginia
  • Centre for Lymphoid Cancer
  • University of British Columbia
  • Stanford University
  • Johns Hopkins University
  • Rutgers - The State University of New Jersey, New Brunswick
  • Washington University St. Louis
  • Indiana University Bloomington
  • Kaiser Permanente
  • Emory University
  • University of Oklahoma
  • University of Alabama at Birmingham
  • Columbia University
  • Memorial Sloan-Kettering Cancer Center
  • Brown University

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Abstract: The phase 1/2 Intergroup study E4412 investigated checkpoint blockade with nivolumab (Nivo) and ipilimumab (Ipi) combined with the CD30 targeting antibody-drug conjugate brentuximab vedotin (BV) in relapsed/refractory classic Hodgkin lymphoma. A total of 147 patients aged ≥12 years were randomized between BV/Nivo and BV/Ipi/Nivo; 132 patients were included in the primary efficacy analysis. The complete response (CR) rate, was 64.7% (52.2, 75.9) for BV/Nivo and 70.3% (57.6, 81.1) for BV/Ipi/Nivo (1-sided P = .29). The median survival follow-up was 38.0 months (interquartile range, 32.6-48.1). Progression-free survival (PFS) did not significantly differ between the 2 arms (hazard ratio [HR], 0.78, confidence interval [CI], 0.39-1.57; 1-sided P = .24). Treatment-related grade 3+ toxicities in the adult cohort, excluding rash, were similar between both arms (38.5% BV/Nivo and 39.3% BV/Ipi/Nivo); there was a higher frequency of grade 3 rash with BV/Ipi/Nivo (24.6%) compared with BV/Nivo (9.2%). We compared PFS by stem cell transplantation (SCT) status in a planned before hoc comparison; 58 patients received SCT, and 36-month PFS (from SCT) was >90% for both arms. Sixty-six patients were progression free after the first scan and did not undergo SCT. The 36-month PFS was 73.0% (54.5, 85.0) for BV/Ipi/Nivo compared with 45.8% (26.3, 63.4) for BV/Nivo (HR, 0.45; CI, 0.19-1.08; 1-sided P = .03). The study did not meet its primary end point of superior CR rate for the triplet, but it supports the use of checkpoint antibody-drug conjugate induction prior to auto SCT, and there is an intriguing signal of disease control for patients wishing to defer or avoid SCT with the triplet of BV/Ipi/Nivo. This trial was registered at www.clinicaltrials.gov as NCT01896999.

Original languageEnglish
Pages (from-to)2041-2052
Number of pages12
JournalBlood
Volume147
Issue number18
DOIs
StatePublished - Apr 30 2026

Fingerprint

Dive into the research topics of 'A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this